About Us

The Team

The core of ZuriMED is built by its people. Our interdisciplinary and diverse team is backed by a strong board of directors comprised of world-renowned experts. Together, we aim to push the boundaries of current orthopedic and sports medicine solutions through our innovative technologies.

Xiang Li - CEO & Co-Founder

Xiang holds a Dr. sc. ETH Zurich degree in Orthopaedic Biomechanics and has over 15 years of experience in medical engineering. Alongside business development, he has built strong expertise in finance, legal, quality, and management. With a clear vision and entrepreneurial mindset, he leads operations, fosters an engaging work environment, and motivates the team to drive innovation and create value.

Xiang Li

CEO & Co-Founder

Elias Bachmann - CTO & Co-Founder

After completing his biomedical engineering studies, Elias spent several years as a research fellow at the Laboratory of Orthopaedic Biomechanics, Balgrist University Hospital, and ETH Zurich. His journey led him to co-found ZuriMED Technologies AG, where he is now responsible for the technical direction, strategy and development.

Elias Bachmann

CTO & Co-Founder

Pol Banzet - Chief Production Officer

With a background in Mechanical Engineering, Pol spent time at Harvard’s Biodesign Lab and at ETH’s Computational Robotics Laboratory before joining ZuriMED early in 2020. He now leads industrialization and lifecycle management, overseeing the transition to scalable manufacturing, ensuring robust manufacturing processes and continuous improvement of medical devices from market launch onward.

Pol Banzet

Chief Production Officer

Sascha Brun - Head of Development

Sascha holds an MSc in Mechanical Engineering, specializing in Robotics and Mechatronics, from ETH Zurich. He leads the development of powered devices at ZuriMED. After a traineeship at the Helbling Robotics Team and a research assistant position at the biomechanics lab, Sascha joined ZuriMED from the early days on.

Sascha Brun

Head of Development

Andrea Möhl - Head of Clinical Affairs

Andrea, Head of Clinical Affairs, holds an MSc in Health Science and Technology from ETH Zurich. She leads pre-clinical and clinical studies, playing a pivotal role in clinical evaluation processes. After a traineeship at DePuy Synthes and a research internship in the rehabilitation engineering field, Andrea joined ZuriMED for her master’s thesis and supported the Surgical-Fiberlock technology project from its early stages.

Andrea Möhl

Head of Clinical Affairs

Sebastian Arevalo - Head of Quality

Sebastian leads ZuriMED's quality and regulatory compliance department. Backed by more than six years of experience in Medtech and a certification as a lead auditor, Sebastian is instrumental in ensuring that all compliance measures and quality standards are met, upholding and advancing the company's commitment to quality, compliance, and continuous improvement.

Sebastian Arevalo

Head of Quality

Show all Team Members ▼

Our Board of Directors is comprised of world-leading scientists, consultants and clinicians supporting the company in their field of expertise.

Prof. Dr. Jess Snedeker

President of the Board of Directors

Ulrich Looser

Member of the Board of Directors

Tyler Beeson

Member of the Board of Directors

Dr. med. Dominique Tschudi

Vice President of the Board of Directors

Dr. Helen (Ying) Yang

Member of the Board of Directors

Dr. Xiang Li

Member of the Board of Directors

Prof. Dr. Robert Frigg

Member of the Board of Directors

Chan-Yuan Lu

Member of the Board of Directors

Join the Team!

Junior Event & Administration Manager

We are seeking a proactive and highly organized Accounting Associate.

Junior Lifecycle Engineer

We are looking for a highly motivated and dynamic junior lifecycle engineer to join our industrialization and lifecycle team.

Get to Know Us

ZuriMED originated in Zurich, Switzerland, and is part of the Swiss health cluster. Surrounded by world-leading universities and orthopedic healthcare institutes, we have unique access to high-quality labs, clinical knowledge, and exceptionally skilled talents.

The startup spun off from the University of Zurich and ETH Zurich in 2015 and is supported by Balgrist Beteiligungs AG. With this, we benefit from a close collaboration with research groups and clinicians, accelerating the transition from bench to bedside.

Our Values

Innovation

We embrace creativity and entrepreneurial thinking, developing groundbreaking technologies to pioneer advancements and reshape the future of healthcare.

Ambition

Our relentless pursuit of excellence and our vision of improving patients’ lives drive us to set new benchmarks in the industry.

Reliability

We are committed to creating a working environment where employees can trust each other while delivering high-quality products and services that healthcare professionals as well as patients can rely on.

Our Mission

ZuriMED strives to develop innovative technologies that overcome current limitations in soft tissue repair by leveraging our pragmatic, agile, and motivated team in close collaboration with healthcare professionals.

Our Vision

We envision a future where our products have redefined modern surgical practices to maximize the quality of physicians’ treatment options and patients’ lives.

Sustainability

At ZuriMED, we are driven by the mission of sustainable innovation and guided by our vision for a better future — not only revolutionizing soft tissue repair in sports medicine but also fostering healthy competition in the MedTech industry while focusing on local environmental impact.

Our Sustainability Goal

Creating a fair workspace where diversity and inclusion are embraced, while focusing on local initiatives and partnerships. We not only take the well-being of our patients and employees seriously but also uphold our responsibility to local communities.

The 12th of February marks the day of the market entry of the FiberLocker System in the U.S. Since then, the reinforcement system is commercially available and can be used for rotator cuff augmentation in the clinical setting.

Furthermore, a first-in-human clinical study in Switzerland and a multicenter clinical study in the U.S. have been initiated.

In December 2024, ZuriMED Technologies AG celebrated a significant achievement: the FDA clearance of our 510(k) submission for the FiberLocker® System. This represents the first clinical indication of the pioneering Surgical-Fiberlock® technology. We anticipate a limited U.S. market release of the SpeedPatch® PET and FiberLocker® Instrument in early 2025, allowing patients to soon benefit from this new technology.

The financing round was led by Chindex Medical Limited (Hong Kong), followed by Yellowstone Holding AG (Geneva) and a group of private investors that includes leading orthopaedic surgeons from Switzerland, Germany, France, and the United States. An additional non-diluting funding from Innosuisse will greatly expedite the development and regulatory registration process of a second clinical indication.

Thanks to this award, ZuriMED can access the second phase of the Scale-up Coaching program to further accelerate the growth in Switzerland and the expansion into new global markets. The Project Grant supports the co-development with research partner University Hospital Balgrist on ZuriMED’s breakthrough technology for soft tissue repair.

ZuriMED achieves ISO 13485 certification through BSI

One of ZuriMED’s endocortical fixation technologies for soft tissue repair has been licensed to an international medical device company. A strategic partnership has been established to work together to bring this technology to clinical applications.

The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. The role of Innosuisse – the Swiss Innovation Agency – is to promote science-based innovation in the interests of industry and society in Switzerland.

Loan conversion of the seed round investment into equity.

Clinical trial on ZuriMED’s first product, the BTB-Converter™ was approved by Swissethics and sponsored by Innosuisse (formerly Commission for Technology and Innovation in Switzerland [CTI]).

Investment in terms of convertible loan. ZuriMED moves into the newly opened Balgrist Campus.

Winner of Venture Kick Final, Switzerland’s largest start-up acceleration program. Presenting 2nd best business plan by >>venture>>, the leading competition for entrepreneurs in Switzerland, a joint initiative of ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL.

BTB-Converter™

Knee ligament reconstruction

Eight years of advanced biomaterial research and translational development at the University and ETH Zürich, in collaboration with leading Swiss surgeons, has led to ZuriMED’s Bone-Tendon-Bone (BTB)-Converter™ for knee ligament reconstruction.

This technology was developed by ZuriMED in the past and has now been out-licensed.

VariLoop™

Superior ligament fixation

The single-strand VariLoop™ enables superior ligament fixation. It is simple, easy to use, self-flipping, and truly knotless. The technology’s high reliability and strength have been proven under all testing conditions. This implant can be used in various configurations for many indications where tension or compression is critical for healing.

This technology was developed by ZuriMED in the past and has now been out-licensed.